Table 3.

Results from Univariable Mendelian Randomization on Each Lipid Fraction in Turn

Lipid Fraction	Method	AMD	CAD	ALZ∗
LDL-c	Inverse-variance weighted	0.94 (0.82–1.09)	1.53 (1.40–1.67)	1.02 (0.93–1.12)
		P = 0.41	P = 2×10−14	P = 0.67
	MR-Egger	0.88 (0.70–1.11)	1.61 (1.39–1.85)	1.05 (0.89–1.24)
		P = 0.28	P = 9×10−9	P = 0.56
	Weighted median	0.91 (0.80–1.02)	1.59 (1.45–1.73)	1.04 (0.92–1.18)
		P = 0.11	P = 3×10−25	P = 0.49
HDL-c	Inverse-variance weighted	1.22 (1.03–1.44)	0.85 (0.76–0.95)	0.98 (0.88–1.09)
		P = 0.02	P = 0.005	P = 0.76
	MR-Egger	1.08 (0.82–1.42)	1.10 (0.93–1.31)	0.91 (0.76–1.09)
		P = 0.58	P = 0.26	P = 0.32
	Weighted median	1.46 (1.23–1.74)	0.95 (0.87–1.05)	1.05 (0.92–1.20)
		P = 3×10−5	P = 0.32	P = 0.46
Triglycerides	Inverse-variance weighted	0.85 (0.67–1.07)	1.30 (1.17–1.45)	0.98 (0.88–1.09)
		P = 0.16	P = 1×10−5	P = 0.68
	MR-Egger	1.31 (0.93–1.86)	1.09 (0.93–1.29)	1.06 (0.89–1.27)
		P = 0.13	P = 0.31	P = 0.51
	Weighted median	1.13 (0.95–1.34)	1.25 (1.12–1.38)	1.00 (0.85–1.17)
		P = 0.17	P = 3×10−5	P = 0.97

ALZ = Alzheimer's disease; AMD = age-related macular degeneration; CAD = coronary artery disease; HDL-c = high-density lipoprotein cholesterol; LDL-c = low-density lipoprotein cholesterol; MR = Mendelian randomization.

Estimates are odds ratios (95% confidence intervals) for the effect of a 1 standard deviation increase in the lipid fraction. All genetic variants that are associated with the lipid fraction at a genome-wide level of significance (P < 5×10⁻⁸) are included in the analysis for that lipid fraction.

^∗Variants from the APOE gene region were omitted from analyses for Alzheimer's disease because they dominated the results.